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Objectives: Despite a decreasing mortality and morbidity in treated HIV-1 patients, highly active antiretroviral
treatment (HAART) can still fail due to the development of drug resistance. Especially, multidrug-resistant
viruses pose a threat to efficient therapy. We studied the changing prevalence of multidrug resistance (MDR)
over time in a cohort of HIV-1-infected patients in Portugal.
Patients and methods: We used data of 8065 HIV-1-infected patients followed from July 2001 up to April 2012
in 22 hospitals located in Portugal. MDR at a specific date of sampling was defined as no more than one fully
active drug (excluding integrase and entry inhibitors) at that time authorized by the Portuguese National
Authority of Medicines and Health Products (INFARMED), as interpreted with the Rega algorithm version
8.0.2. A generalized linear mixed model was used to study the time trend of the prevalence of MDR.
Results: We observed a statistically significant decrease in the prevalence of MDR over the last decade, from
6.9% (95% CI: 5.7–8.4) in 2001–03, 6.0% (95% CI: 4.9–7.2) in 2003–05, 3.7% (95% CI: 2.8–4.8) in 2005–07
and 1.6% (95% CI: 1.1–2.2) in 2007–09 down to 0.6% (95% CI: 0.3–0.9) in 2009–12 [OR¼0.80 (95% CI:
0.75–0.86); P,0.001]. In July 2011 the last new case of MDR was seen.
Conclusions: The prevalence of multidrug-resistant HIV-1 is decreasing over time in Portugal, reflecting the in-
creasing efficiency of HAART and the availability of new drugs. Therefore, in designing a new drug, safety and
practical aspects, e.g. less toxicity and ease of use, may need more attention than focusing mainly on efficacy
against resistant strains.
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Introduction
In 2012, clinicians in higher-income countries can choose out of
25 different FDA-approved anti-HIV-1 drugs to set up a potent
highly active antiretroviral therapy (HAART).1 Nevertheless, in
many patients not all options can be used, due to intolerance
or side effects for certain drugs and because of the presence
of antiviral drug (cross-)resistance.2 This cross-resistance can
be so severe that no efficient HAART can be composed,
because nearly all drugs are affected.3 – 5 Fortunately, multidrug
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resistance (MDR) to anti-HIV-1 drugs has been decreasing in
recent years in patients failing therapy and drug developers
have been encouraged to focus their research on new potent
drugs with a better tolerability, ease of use and less toxicity.6,7
This paper analysed the trend of MDR in Portugal from the
moment that resistance testing became routine clinical practice
in cases of treatment failure—i.e. July 2001—until the current
date—i.e. April 2012. We aimed to quantify to what extent the
issue of MDR still exists today.
Patients and methods
A Portuguese database, covering 22 hospitals located over the entire
country and containing HIV-drug resistance data and clinical data of
HIV-infected patients, was consulted in April 2012. Resistance data
and, if available, start date of initial therapy were retrieved for 8065
HIV-1-infected patients who had undergone at least one drug resistance
test from July 2001 to March 2012. No Ethics Committee approval was
required. The vast majority of samples were tested at Hospital Egas
Moniz in Lisbon, the major reference laboratory in Portugal. The Rega al-
gorithm (version 8.0.2) was used to interpret the susceptibility to drugs
for 10286 viral pol sequences. The studied drugs belong to the three
major drug classes (nucleoside reverse transcriptase inhibitors, non-
nucleoside reverse transcriptase inhibitors and protease inhibitors) and
all are authorized by the National Authority of Medicines and Health
Products (INFARMED) in Portugal.8 A virus was defined to be multidrug
resistant at a specific date of sampling, when no more than one drug
authorized by the Portuguese INFARMED (but excluding entry and inte-
grase inhibitors) was still fully active at that timepoint (see Figure 1),
reflecting the difficulty of selecting an efficient HAART regimen. The
prevalence of MDR in a certain time interval was calculated as the propor-
tion of patients with MDR among those who had at least one sample for
resistance testing in that time interval. Prevalence per 2 years was mod-
elled over time and graphically visualized using a (univariate) Poisson re-
gression model. The majority of the patients (81.1%) had only one
resistance test in the dataset. Nevertheless, a generalized linear mixed
model (GLMM) was used in order to test the significance of the time
trend of drug resistance, taking into account the correlation among mul-
tiple samples per patient. Finally, the model was adjusted for those con-
founding factors for which there were data available: duration on therapy
and incomplete initial start date of therapy. The data were analysed
using the free statistical software R (version 2.10.1).
Results
We observed a decrease in the prevalence of MDR over the last
decade, from 6.9% (95% CI: 5.7–8.4) in 2001–03, 6.0% (95%
CI: 4.9–7.2) in 2003–05, 3.7% (95% CI: 2.8–4.8) in 2005–07
and 1.6% (95% CI: 1.1–2.2) in 2007–09 down to 0.6% (95% CI:
0.3–0.9) in 2009–12. Prevalence and Poisson trend lines are
shown in Figure 2. This decreasing trend was confirmed to be stat-
istically significant by GLMM: for every consecutive year, the odds
of having multidrug-resistant cases decreased by 17% (OR¼0.83;
95% CI: 0.82–0.84; P,0.001). Furthermore, GLMM showed signifi-
cant effects for the confounding factors: for every extra year on
therapy, the odds of evolving to MDR increased by 23%
(OR¼1.23; 95% CI: 1.21–1.24; P,0.001). Patients with an incom-
plete initial start date of therapy (n¼1148, 14.2%) were more
than three times more likely to develop MDR (OR¼2.67; 95% CI:
2.41–2.96; P,0.001), which may reflect the fact that these
patients started therapy before the HAART era, when therapy
initiation records were not recorded electronically.
Discussion
Over the last three decades, antiretroviral therapy has become
more effective and drug resistance testing strategies have
improved. Despite a clear pattern of increasing antiretroviral re-
sistance in lower-income settings,9,10 there have been recent
reports on declining trends of resistance in high-income coun-
tries.6,7,11,12 Therefore, we questioned whether current regimens
are still selecting for MDR. Our previous analysis showed a signifi-
cant decreasing trend of MDR from 2001 to 2006, but used a
rather conservative approach by taking into account only those
drugs available over the total study period.7 Moreover, if a
patient had more than one sample for resistance testing, con-
secutive samples were only taken into consideration if an
earlier sample did not show resistance, leading to the calculation
of incidence, instead of the more intuitive prevalence, and
causing data loss. In this study, all anti-HIV-1 drugs were consid-
ered as potential candidates for setting up a new treatment,
from the moment they were authorized by the Portuguese
INFARMED. This is clinically more relevant as these drugs
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July 2001 : start analysis: MDR is defined as at most one active drug among:
3TC, ZDV, ddC, ddI, d4T, ABC, EFV, NVP, FPV/r, IDV/r, SQV/r, LPV/r and NFV
+TDF (2 May 2002)
+FTC (24 Oct 2003)
+ATV/r (3 Feb 2004)
+TPV/r (25 Oct 2005)
-ddC (12 Jun 2006)
+DRV/r (2 Dec 2007)
+ETV (28 Sep 2008)
Figure 1. Overview of anti-HIV drugs used in the definition of MDR based on dates of authorization by the Portuguese INFARMED. A virus was defined
to be multidrug resistant at a specific date of sampling, when no more than one drug on this list was still fully active at that timepoint. 3TC,
lamivudine; ZDV, zidovudine; ddC, zalcitabine; ddI, didanosine; d4T, stavudine; ABC, abacavir; EFV, efavirenz; NVP, nevirapine; FPV/r, boosted
fosamprenavir; IDV/r, boosted indinavir; SQV/r, boosted saquinavir; LPV/r, boosted lopinavir; NFV, nelfinavir; TDF, tenofovir; FTC, emtricitabine; ATV/r,
boosted atazanavir; TPV/r, boosted tipranavir; DRV/r, boosted darunavir; ETV, etravirine.
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represent the choices that the treating clinician had at the time
of therapy failure. The following drugs were not taken into
account and can still exhibit antiviral activity: maraviroc (infor-
mation on viral tropism was not available for all patients), enfu-
virtide (information on gp41-associated resistance was not
available), raltegravir (integrase genotype information was not
available for all patients) and rilpivirine (no rules for this
newest drug are available as yet in the Rega algorithm); thus,
the latest MDR prevalence may even be lower. Furthermore, by
using a GLMM, the correlation between resistance information
of consecutive samples of the same patient is taken into
account. Nevertheless, since routine resistance testing in cases
of treatment failure in Portugal was consistently conducted
only from July 2001 onwards, only samples from that date
onwards were taken into consideration, reducing the bias of
left censoring. Following this approach, we saw a statistically sig-
nificant downwards trend of MDR (2001–12). This result was cor-
rected for two confounding factors: (i) the duration on therapy at
which patients are genotypically tested; and (ii) the fact that for
a number of patients the initial start date of therapy was not
exactly known, which may reflect the fact that these patients
started therapy before 1998, when therapy initiation records
were finally kept electronically. It can be argued that at the be-
ginning of our study period, resistance testing started to be
implemented in routine clinical practice, such that relatively
more advanced and drug resistance patients were tested for
the first time (left-censoring bias). To cope with this problem,
patients with samples that showed MDR before July 2001 were
excluded from the analysis of MDR. While this may not have
eliminated the bias entirely, the continuing decreasing trends
of MDR even in the most recent years suggests that these are
genuine.
In Portugal, multidrug-resistant HIV-1 seems to vanish over
time: in July 2011 the last new case of MDR was seen (incidence
data not shown). No more new cases of MDR does not mean that
resistance will disappear completely, as can be seen by several
drugs that are still showing a high prevalence of resistance in
2012.13 Resistance to the newest agents can emerge, resulting
in the appearance of novel drug resistance mutations in the
HIV-1 polymerase, integrase and envelope genes.5 Moreover,
as a consequence of ongoing transmission of drug resistance,
newly infected patients may already have drug-resistant virus.
However, as the list of candidate drugs for use in follow-up regi-
mens after therapy failure is still expanding, the occurrence of
multidrug-resistant HIV-1 for which an efficient treatment with
at least three potent drugs is not possible is increasingly rare.
Moreover, the demise of MDR follows the improving therapy
and drug resistance testing strategies in high-income countries.
These results are based on nationwide data from the past
decade in Portugal and, in our opinion, are likely to reflect resist-
ance trends in other high-income countries with similar access to
antiretroviral therapy regimens. This information is of great im-
portance for drug developers, who are encouraged to focus
more on better tolerability and ease of use of the drug rather
than developing potent antiretroviral agents targeted at over-
coming resistance.
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